SynthesisCancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology2026
Helicobacter pylori Infection and Metabolic Dysfunction-Associated Steatotic Liver Disease: A Prospective Study and Meta-Analysis.
Synthesis in Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors.
Funding
Abstract
backgroundHelicobacter pylori infection and metabolic dysfunction-associated steatotic liver disease (MASLD) are significant global health concerns, but their association remains unclear, with evidence mainly from cross-sectional studies and Asian populations.
methodsWe analyzed UK Biobank (UKB) participants ages 40 to 69 years with objectively measured H. pylori serostatus data (N = 4,246). Cox models estimated hazard ratios (HR) and 95% confidence intervals (CI), adjusting for demographic, lifestyle, and cardiometabolic factors. We meta-analyzed seven prospective cohorts (all from non-European populations) and the UKB (8 cohorts in total with 36,145 participants and 6,979 cases) to evaluate the association between H. pylori seropositivity and MASLD risk.
resultsAbout 35.1% of the participants were seropositive for H. pylori in the UKB. With a median follow-up of 11.1 years, we identified 32 MASLD cases. H. pylori seropositivity was marginally associated with higher MASLD risk (HR, 1.88; 95% CI, 0.92-3.82), whereas cytotoxin-associated gene A (CagA) seropositivity was significantly associated with higher risk (2.40; 1.17-4.92). Participants seropositive for both H. pylori and CagA had a higher MASLD risk than participants seronegative for both markers (2.58; 1.19-5.61). The meta-analysis showed that H. pylori was associated with a 24% higher MASLD risk (risk ratio, 1.24; 95% CI, 1.17-1.31).
conclusionsH. pylori infection, particularly CagA seropositivity, was associated with higher MASLD risk in prospective studies. IMPACT: Our findings support a potential role of H. pylori virulence serology (CagA) in MASLD development. If confirmed, these findings could have implications for risk stratification and inform targeted eradication or prevention strategies.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.